Crispr Therapeutics (CRSP) - News Mentions

Sign up to add (CRSP) to your portfolio and access more historical data.

10%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 2 0%
Gilead Sciences
Gilead Sciences
GILD		 1 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 100%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 1 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Stifel Financial Corp Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
December 21
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by State Street Corp
December 15
Zacks Research Analysts Decrease Earnings Estimates for CRSP
December 13
Chardan Capital Reaffirms “Buy” Rating for CRISPR Therapeutics (NASDAQ:CRSP)
December 12
FY2024 Earnings Estimate for CRSP Issued By William Blair
December 11
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
December 11
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
December 6
BNP Paribas Financial Markets Sells 48,467 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
December 5
Fmr LLC Purchases 23,075 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
December 5
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
December 5
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Brokerages
December 3
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
December 2
What is Zacks Research’s Estimate for CRSP FY2024 Earnings?
November 28
Advisors Asset Management Inc. Acquires 342 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
November 28
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Swiss National Bank
November 26
Banque Cantonale Vaudoise Has $804,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
November 22

Month over Month

Est. daily news mentions.

Nov 2024 0
Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0

How often is Crispr Therapeutics mentioned in the news?

Crispr Therapeutics was mentioned an estimated 1 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Crispr Therapeutics performing compared to its industry peers?

Crispr Therapeutics underperforms its industry peers when it comes to News Mentions, ranking in the 33rd percentile.

Has there been an increase or decrease in news mentions of Crispr Therapeutics in the last month?

There has been no significant change in the number of news mentions for Crispr Therapeutics' compared to the last month.

Why is it important to track news mentions for Crispr Therapeutics?

By monitoring mentions in the news for Crispr Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Crispr Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on Crispr Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact